Consortium Partners

Print

The Biomarkers Consortium brings together the expertise and resources of various partners to rapidly identify, develop, and qualify potential high-impact biomarkers for use in research, therapeutic and diagnostic development and approval, and clinical practice.

All public- and private-sector partners are involved in consortium governance and contribute their scientific and technical expertise as advisors to the effort. In addition, public partners--NIH, FDA, CMS, and other federal agencies--may contribute financial resources and manage the conduct of projects under the consortium. Private-sector partners--corporations, non-profit organizations and associations, and advocacy groups--provide both financial contributions to help support the consortium's overall operations and may also fund individual projects conducted by the consortium.

Through their generous commitments of financial resources and scientific insights to this initiative, The Biomarkers Consortium partners help ensure that the consortium lives up to its promise of speeding disease-specific research and ensuring that safe, innovative, and effective medicines and diagnostics are expeditiously developed to address healthcare needs, improve medical care, and promote and improve public health.

Learn more about Consortium partners:

Government partners
Industry partners
Non-profit partners

The Foundation for NIH is actively seeking additional partners, and encourages other corporations, non-profit and associations, advocacy organizations, and philanthropic organizations to participate in The Biomarkers Consortium.

For further information about supporting The Biomarkers Consortium, please contact David Lee at .

 

  • About Biomarkers

    Biomarkers are characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to therapeutic intervention. More

  • Join Us

    Become a Member
    Learn how you can join and support The Biomarkers Consortium.

    The Biomarkers Consortium embraces government, industry, patient advocacy groups, and non-profit organizations, each of which has a stake in the development of biomarker technology.

  • Latest News

    THE BIOMARKERS CONSORTIUM LAUNCHES I-SPY 2 BREAST CANCER CLINICAL TRIAL:  Click here to read the press release.

    March 17, 2010 -- Announcing the launch of the Biomarkers Consortium I-SPY 2 TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging and moLecular analysis): An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy), which is taking place today from 9-10:30 a.m. ET at the National Press Club, Washington, DC.  Click here for more information.

    View the Web Cast

     

    Six awardees conducting data analysis to Develop Clinical Criteria for the Diagnosis of Clinically Important Weakness Associated with Low Muscle Mass in Older Adults: Click here to read

    The Metabolic Disorders Steering Committee releases strategy for Mathematical Modeling in Atherosclerosis:  Details

    PRESS RELEASE:  The Biomarkers Consortium Completes First Project to Show That Adiponectin is a Predictive Biomarker for Type 2 Diabetes:  Click here to read

    RFP for Data Analysis to Develop Clinical Criteria for the Diagnosis of Clinically Important Weakness Associated with Low Muscle Mass in Older Adults.  Due Date: September 8, 2009.  Click here to read.

     

    Available Now: The Biomarkers Consortium Report, Volume 1, Issue 1, May 2009. Click Here to Read

    The Metabolic Disorders Steering Committee Prioritized Areas of Unmet Need: As advertised in Volume 58, No. 4, April 2009 issue of Diabetes.  Click Here to read.

    Presentations Available from the Beta Cell Function Symposium. Click here for agenda.